A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

Sponsor
Eli Lilly and Company
Study ID
NCT06635057
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.

Key Dates

Start date
Oct 11, 2024
Status verified
May 2026
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026

Study Design

Enrollment
166 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tirzepatide
    Participants will receive tirzepatide subcutaneously (SC)

Primary Outcome Measure

Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from Start of Ramadan (SoR) ]

Related Studies